The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Human Follicle-stimulating Hormone Market Research Report 2025
Synopsis
Recombinant Human Follicle-Stimulating Hormone (r-hFSH) is a biotechnologically produced hormone that plays a crucial role in the human reproductive system. It is a synthetic form of the naturally occurring follicle-stimulating hormone (FSH), which is produced by the anterior pituitary gland in the brain. FSH is essential for the regulation of the female and male reproductive systems and is involved in processes like ovarian follicle development, sperm production, and the maturation of reproductive cells.
The global Recombinant Human Follicle-stimulating Hormone market was valued at US$ 1045.6 million in 2023 and is anticipated to reach US$ 1523 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
Increasing Demand for Assisted Reproductive Technologies (ART): The growing acceptance of ART, including in vitro fertilization (IVF), is driving the demand for r-hFSH. ART is used by individuals and couples to address infertility issues, and r-hFSH plays a vital role in controlled ovarian stimulation.
Advancements in ART Procedures: Ongoing advancements in ART procedures are leading to increased use of r-hFSH. These procedures continue to improve success rates, which further fuels demand.
Expanded Indications: The use of r-hFSH is being explored for a broader range of indications, including for individuals with specific hormonal imbalances or other medical conditions that affect reproductive health.
Personalized Medicine: Tailoring treatment regimens to individual patients is gaining importance. Clinicians are increasingly using r-hFSH in personalized fertility treatment plans, optimizing the chances of success while minimizing side effects.
Global Expansion: The use of r-hFSH is expanding globally as countries invest in reproductive healthcare infrastructure. Emerging markets are showing increased demand for fertility treatments and related products.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Follicle-stimulating Hormone, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Follicle-stimulating Hormone.
Report Scope
The Recombinant Human Follicle-stimulating Hormone market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Follicle-stimulating Hormone market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Follicle-stimulating Hormone companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical
Segment by Type
75IU
150IU
Others
Segment by Application
Infertility Treatment
Assisted Reproductive Technology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Human Follicle-stimulating Hormone companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Recombinant Human Follicle-Stimulating Hormone (r-hFSH) is a biotechnologically produced hormone that plays a crucial role in the human reproductive system. It is a synthetic form of the naturally occurring follicle-stimulating hormone (FSH), which is produced by the anterior pituitary gland in the brain. FSH is essential for the regulation of the female and male reproductive systems and is involved in processes like ovarian follicle development, sperm production, and the maturation of reproductive cells.
The global Recombinant Human Follicle-stimulating Hormone market was valued at US$ 1045.6 million in 2023 and is anticipated to reach US$ 1523 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
Increasing Demand for Assisted Reproductive Technologies (ART): The growing acceptance of ART, including in vitro fertilization (IVF), is driving the demand for r-hFSH. ART is used by individuals and couples to address infertility issues, and r-hFSH plays a vital role in controlled ovarian stimulation.
Advancements in ART Procedures: Ongoing advancements in ART procedures are leading to increased use of r-hFSH. These procedures continue to improve success rates, which further fuels demand.
Expanded Indications: The use of r-hFSH is being explored for a broader range of indications, including for individuals with specific hormonal imbalances or other medical conditions that affect reproductive health.
Personalized Medicine: Tailoring treatment regimens to individual patients is gaining importance. Clinicians are increasingly using r-hFSH in personalized fertility treatment plans, optimizing the chances of success while minimizing side effects.
Global Expansion: The use of r-hFSH is expanding globally as countries invest in reproductive healthcare infrastructure. Emerging markets are showing increased demand for fertility treatments and related products.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Follicle-stimulating Hormone, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Follicle-stimulating Hormone.
Report Scope
The Recombinant Human Follicle-stimulating Hormone market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Follicle-stimulating Hormone market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Follicle-stimulating Hormone companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical
Segment by Type
75IU
150IU
Others
Segment by Application
Infertility Treatment
Assisted Reproductive Technology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Human Follicle-stimulating Hormone companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Human Follicle-stimulating Hormone Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 75IU
1.2.3 150IU
1.2.4 Others
1.3 Market by Application
1.3.1 Global Recombinant Human Follicle-stimulating Hormone Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Infertility Treatment
1.3.3 Assisted Reproductive Technology
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Human Follicle-stimulating Hormone Market Perspective (2019-2030)
2.2 Recombinant Human Follicle-stimulating Hormone Growth Trends by Region
2.2.1 Global Recombinant Human Follicle-stimulating Hormone Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant Human Follicle-stimulating Hormone Historic Market Size by Region (2019-2024)
2.2.3 Recombinant Human Follicle-stimulating Hormone Forecasted Market Size by Region (2025-2030)
2.3 Recombinant Human Follicle-stimulating Hormone Market Dynamics
2.3.1 Recombinant Human Follicle-stimulating Hormone Industry Trends
2.3.2 Recombinant Human Follicle-stimulating Hormone Market Drivers
2.3.3 Recombinant Human Follicle-stimulating Hormone Market Challenges
2.3.4 Recombinant Human Follicle-stimulating Hormone Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Human Follicle-stimulating Hormone Players by Revenue
3.1.1 Global Top Recombinant Human Follicle-stimulating Hormone Players by Revenue (2019-2024)
3.1.2 Global Recombinant Human Follicle-stimulating Hormone Revenue Market Share by Players (2019-2024)
3.2 Global Recombinant Human Follicle-stimulating Hormone Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Human Follicle-stimulating Hormone Revenue
3.4 Global Recombinant Human Follicle-stimulating Hormone Market Concentration Ratio
3.4.1 Global Recombinant Human Follicle-stimulating Hormone Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Human Follicle-stimulating Hormone Revenue in 2023
3.5 Recombinant Human Follicle-stimulating Hormone Key Players Head office and Area Served
3.6 Key Players Recombinant Human Follicle-stimulating Hormone Product Solution and Service
3.7 Date of Enter into Recombinant Human Follicle-stimulating Hormone Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Human Follicle-stimulating Hormone Breakdown Data by Type
4.1 Global Recombinant Human Follicle-stimulating Hormone Historic Market Size by Type (2019-2024)
4.2 Global Recombinant Human Follicle-stimulating Hormone Forecasted Market Size by Type (2025-2030)
5 Recombinant Human Follicle-stimulating Hormone Breakdown Data by Application
5.1 Global Recombinant Human Follicle-stimulating Hormone Historic Market Size by Application (2019-2024)
5.2 Global Recombinant Human Follicle-stimulating Hormone Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Recombinant Human Follicle-stimulating Hormone Market Size (2019-2030)
6.2 North America Recombinant Human Follicle-stimulating Hormone Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024)
6.4 North America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Human Follicle-stimulating Hormone Market Size (2019-2030)
7.2 Europe Recombinant Human Follicle-stimulating Hormone Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024)
7.4 Europe Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Size (2019-2030)
8.2 Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Size by Region (2019-2024)
8.4 Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Human Follicle-stimulating Hormone Market Size (2019-2030)
9.2 Latin America Recombinant Human Follicle-stimulating Hormone Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024)
9.4 Latin America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Size (2019-2030)
10.2 Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024)
10.4 Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Recombinant Human Follicle-stimulating Hormone Introduction
11.1.4 Merck Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Ferring
11.2.1 Ferring Company Detail
11.2.2 Ferring Business Overview
11.2.3 Ferring Recombinant Human Follicle-stimulating Hormone Introduction
11.2.4 Ferring Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.2.5 Ferring Recent Development
11.3 Livzon
11.3.1 Livzon Company Detail
11.3.2 Livzon Business Overview
11.3.3 Livzon Recombinant Human Follicle-stimulating Hormone Introduction
11.3.4 Livzon Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.3.5 Livzon Recent Development
11.4 Gedeon Richter
11.4.1 Gedeon Richter Company Detail
11.4.2 Gedeon Richter Business Overview
11.4.3 Gedeon Richter Recombinant Human Follicle-stimulating Hormone Introduction
11.4.4 Gedeon Richter Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.4.5 Gedeon Richter Recent Development
11.5 GenSci
11.5.1 GenSci Company Detail
11.5.2 GenSci Business Overview
11.5.3 GenSci Recombinant Human Follicle-stimulating Hormone Introduction
11.5.4 GenSci Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.5.5 GenSci Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Recombinant Human Follicle-stimulating Hormone Introduction
11.6.4 Teva Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.6.5 Teva Recent Development
11.7 ChangChun High & New Technology
11.7.1 ChangChun High & New Technology Company Detail
11.7.2 ChangChun High & New Technology Business Overview
11.7.3 ChangChun High & New Technology Recombinant Human Follicle-stimulating Hormone Introduction
11.7.4 ChangChun High & New Technology Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.7.5 ChangChun High & New Technology Recent Development
11.8 ABL
11.8.1 ABL Company Detail
11.8.2 ABL Business Overview
11.8.3 ABL Recombinant Human Follicle-stimulating Hormone Introduction
11.8.4 ABL Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.8.5 ABL Recent Development
11.9 Scripps Laboratories
11.9.1 Scripps Laboratories Company Detail
11.9.2 Scripps Laboratories Business Overview
11.9.3 Scripps Laboratories Recombinant Human Follicle-stimulating Hormone Introduction
11.9.4 Scripps Laboratories Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.9.5 Scripps Laboratories Recent Development
11.10 Alphamab Oncology
11.10.1 Alphamab Oncology Company Detail
11.10.2 Alphamab Oncology Business Overview
11.10.3 Alphamab Oncology Recombinant Human Follicle-stimulating Hormone Introduction
11.10.4 Alphamab Oncology Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.10.5 Alphamab Oncology Recent Development
11.11 Hunan Jingfeng Pharmaceutical
11.11.1 Hunan Jingfeng Pharmaceutical Company Detail
11.11.2 Hunan Jingfeng Pharmaceutical Business Overview
11.11.3 Hunan Jingfeng Pharmaceutical Recombinant Human Follicle-stimulating Hormone Introduction
11.11.4 Hunan Jingfeng Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.11.5 Hunan Jingfeng Pharmaceutical Recent Development
11.12 Qilu Pharmaceutical
11.12.1 Qilu Pharmaceutical Company Detail
11.12.2 Qilu Pharmaceutical Business Overview
11.12.3 Qilu Pharmaceutical Recombinant Human Follicle-stimulating Hormone Introduction
11.12.4 Qilu Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.12.5 Qilu Pharmaceutical Recent Development
11.13 Beijing SL Pharmaceutical
11.13.1 Beijing SL Pharmaceutical Company Detail
11.13.2 Beijing SL Pharmaceutical Business Overview
11.13.3 Beijing SL Pharmaceutical Recombinant Human Follicle-stimulating Hormone Introduction
11.13.4 Beijing SL Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.13.5 Beijing SL Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Recombinant Human Follicle-stimulating Hormone Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of 75IU
Table 3. Key Players of 150IU
Table 4. Key Players of Others
Table 5. Global Recombinant Human Follicle-stimulating Hormone Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Recombinant Human Follicle-stimulating Hormone Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Recombinant Human Follicle-stimulating Hormone Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Recombinant Human Follicle-stimulating Hormone Market Share by Region (2019-2024)
Table 9. Global Recombinant Human Follicle-stimulating Hormone Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Recombinant Human Follicle-stimulating Hormone Market Share by Region (2025-2030)
Table 11. Recombinant Human Follicle-stimulating Hormone Market Trends
Table 12. Recombinant Human Follicle-stimulating Hormone Market Drivers
Table 13. Recombinant Human Follicle-stimulating Hormone Market Challenges
Table 14. Recombinant Human Follicle-stimulating Hormone Market Restraints
Table 15. Global Recombinant Human Follicle-stimulating Hormone Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Recombinant Human Follicle-stimulating Hormone Market Share by Players (2019-2024)
Table 17. Global Top Recombinant Human Follicle-stimulating Hormone Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Follicle-stimulating Hormone as of 2023)
Table 18. Ranking of Global Top Recombinant Human Follicle-stimulating Hormone Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Recombinant Human Follicle-stimulating Hormone Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Recombinant Human Follicle-stimulating Hormone Product Solution and Service
Table 22. Date of Enter into Recombinant Human Follicle-stimulating Hormone Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Recombinant Human Follicle-stimulating Hormone Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Recombinant Human Follicle-stimulating Hormone Revenue Market Share by Type (2019-2024)
Table 26. Global Recombinant Human Follicle-stimulating Hormone Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Recombinant Human Follicle-stimulating Hormone Revenue Market Share by Type (2025-2030)
Table 28. Global Recombinant Human Follicle-stimulating Hormone Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Recombinant Human Follicle-stimulating Hormone Revenue Market Share by Application (2019-2024)
Table 30. Global Recombinant Human Follicle-stimulating Hormone Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Recombinant Human Follicle-stimulating Hormone Revenue Market Share by Application (2025-2030)
Table 32. North America Recombinant Human Follicle-stimulating Hormone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Recombinant Human Follicle-stimulating Hormone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Recombinant Human Follicle-stimulating Hormone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Size by Country (2025-2030) & (US$ Million)
Table 47. Merck Company Detail
Table 48. Merck Business Overview
Table 49. Merck Recombinant Human Follicle-stimulating Hormone Product
Table 50. Merck Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 51. Merck Recent Development
Table 52. Ferring Company Detail
Table 53. Ferring Business Overview
Table 54. Ferring Recombinant Human Follicle-stimulating Hormone Product
Table 55. Ferring Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 56. Ferring Recent Development
Table 57. Livzon Company Detail
Table 58. Livzon Business Overview
Table 59. Livzon Recombinant Human Follicle-stimulating Hormone Product
Table 60. Livzon Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 61. Livzon Recent Development
Table 62. Gedeon Richter Company Detail
Table 63. Gedeon Richter Business Overview
Table 64. Gedeon Richter Recombinant Human Follicle-stimulating Hormone Product
Table 65. Gedeon Richter Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 66. Gedeon Richter Recent Development
Table 67. GenSci Company Detail
Table 68. GenSci Business Overview
Table 69. GenSci Recombinant Human Follicle-stimulating Hormone Product
Table 70. GenSci Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 71. GenSci Recent Development
Table 72. Teva Company Detail
Table 73. Teva Business Overview
Table 74. Teva Recombinant Human Follicle-stimulating Hormone Product
Table 75. Teva Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 76. Teva Recent Development
Table 77. ChangChun High & New Technology Company Detail
Table 78. ChangChun High & New Technology Business Overview
Table 79. ChangChun High & New Technology Recombinant Human Follicle-stimulating Hormone Product
Table 80. ChangChun High & New Technology Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 81. ChangChun High & New Technology Recent Development
Table 82. ABL Company Detail
Table 83. ABL Business Overview
Table 84. ABL Recombinant Human Follicle-stimulating Hormone Product
Table 85. ABL Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 86. ABL Recent Development
Table 87. Scripps Laboratories Company Detail
Table 88. Scripps Laboratories Business Overview
Table 89. Scripps Laboratories Recombinant Human Follicle-stimulating Hormone Product
Table 90. Scripps Laboratories Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 91. Scripps Laboratories Recent Development
Table 92. Alphamab Oncology Company Detail
Table 93. Alphamab Oncology Business Overview
Table 94. Alphamab Oncology Recombinant Human Follicle-stimulating Hormone Product
Table 95. Alphamab Oncology Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 96. Alphamab Oncology Recent Development
Table 97. Hunan Jingfeng Pharmaceutical Company Detail
Table 98. Hunan Jingfeng Pharmaceutical Business Overview
Table 99. Hunan Jingfeng Pharmaceutical Recombinant Human Follicle-stimulating Hormone Product
Table 100. Hunan Jingfeng Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 101. Hunan Jingfeng Pharmaceutical Recent Development
Table 102. Qilu Pharmaceutical Company Detail
Table 103. Qilu Pharmaceutical Business Overview
Table 104. Qilu Pharmaceutical Recombinant Human Follicle-stimulating Hormone Product
Table 105. Qilu Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 106. Qilu Pharmaceutical Recent Development
Table 107. Beijing SL Pharmaceutical Company Detail
Table 108. Beijing SL Pharmaceutical Business Overview
Table 109. Beijing SL Pharmaceutical Recombinant Human Follicle-stimulating Hormone Product
Table 110. Beijing SL Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024) & (US$ Million)
Table 111. Beijing SL Pharmaceutical Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Human Follicle-stimulating Hormone Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Recombinant Human Follicle-stimulating Hormone Market Share by Type: 2023 VS 2030
Figure 3. 75IU Features
Figure 4. 150IU Features
Figure 5. Others Features
Figure 6. Global Recombinant Human Follicle-stimulating Hormone Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Recombinant Human Follicle-stimulating Hormone Market Share by Application: 2023 VS 2030
Figure 8. Infertility Treatment Case Studies
Figure 9. Assisted Reproductive Technology Case Studies
Figure 10. Recombinant Human Follicle-stimulating Hormone Report Years Considered
Figure 11. Global Recombinant Human Follicle-stimulating Hormone Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Recombinant Human Follicle-stimulating Hormone Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Recombinant Human Follicle-stimulating Hormone Market Share by Region: 2023 VS 2030
Figure 14. Global Recombinant Human Follicle-stimulating Hormone Market Share by Players in 2023
Figure 15. Global Top Recombinant Human Follicle-stimulating Hormone Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Follicle-stimulating Hormone as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Recombinant Human Follicle-stimulating Hormone Revenue in 2023
Figure 17. North America Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Recombinant Human Follicle-stimulating Hormone Market Share by Country (2019-2030)
Figure 19. United States Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Recombinant Human Follicle-stimulating Hormone Market Share by Country (2019-2030)
Figure 23. Germany Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Recombinant Human Follicle-stimulating Hormone Market Share by Region (2019-2030)
Figure 31. China Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Recombinant Human Follicle-stimulating Hormone Market Share by Country (2019-2030)
Figure 39. Mexico Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Recombinant Human Follicle-stimulating Hormone Market Share by Country (2019-2030)
Figure 43. Turkey Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Recombinant Human Follicle-stimulating Hormone Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Merck Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 46. Ferring Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 47. Livzon Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 48. Gedeon Richter Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 49. GenSci Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 50. Teva Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 51. ChangChun High & New Technology Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 52. ABL Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 53. Scripps Laboratories Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 54. Alphamab Oncology Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 55. Hunan Jingfeng Pharmaceutical Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 56. Qilu Pharmaceutical Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 57. Beijing SL Pharmaceutical Revenue Growth Rate in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
